GuidelineAnnals of internal medicine2021
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
Guideline in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidelines for the prevention and management of children and adolescents with COVID-19.European journal of pediatrics · 2022Guideline
- Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.Annals of internal medicine · 2021Pooled it
- Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal.Frontiers in medicine · 2021Pooled it
- Reimagining How We Synthesize Information to Impact Clinical Care, Policy, and Research Priorities in Real Time: Examples and Lessons Learned from COVID-19.Journal of general internal medicine · 2024Article
- Therapeutic strategies for COVID-19: progress and lessons learned.Nature reviews. Drug discovery · 2023Review
- Clinical research methodology process: what is changing with COVID-19?European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- One year on: The impact of COVID-19 on clinical research.European journal of internal medicine · 2021Article
- Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.Scientific reports · 2021Article
- A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients.Infection & chemotherapy · 2021Article
- Contemporary narrative review of treatment options for COVID-19.Respirology (Carlton, Vic.) · 2021Review
- Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines.Open forum infectious diseases · 2021Review
- Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule and Rational use Against COVID-19 Based on Literature Mining.Frontiers in pharmacology · 2021Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
- Updated by
- Update of
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.